Modeling bone marrow microenvironment and hematopoietic dysregulation in Gaucher disease through VavCre mediated Gba deletion
Human Molecular Genetics · 2025
DOI: 10.1093/hmg/ddaf045 ↗Kurz gefasst
Fachartikel in der Zeitschrift Human Molecular Genetics, 2025. Verfasst von Glenn Belinsky und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine (Digestive Diseases), Yale School of Medicine, The Anylan Center, 300 Cedar St, New Haven, Connecticut 06519, United States. Hauptthemen laut MEDLINE: Gaucher Disease, Glucosylceramidase, Bone Marrow, Proto-Oncogene Proteins c-vav. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NINDS NIH HHS.
Abstract (Originalsprache)
Biallelic mutations in Gba cause Gaucher disease (GD), a lysosomal disorder characterized by deficient glucocerebrosidase activity and the accumulation of glucosylceramide (GlcCer) and glucosylsphingosine (GlcSph), primarily in macrophages. Beyond macrophages, GD pathology affects additional hematopoietic lineages, contributing to immune dysregulation. Existing Mx1-Cre Gba knockout models require induction protocols that lead to gene deletion outside hematopoietic cells, limiting the study of hematopoietic-specific effects. To overcome these limitations, we generated a hematopoietic-specific Gba knockout model by crossing Gbafl/fl mice with Vav-Cre, enabling early deletion of Gba exons 8–11 in hematopoietic stem and progenitor cells. These mice were backcrossed to 129X1/SvJ and C57BL/6 J backgrounds, revealing that genetic background significantly influences disease severity. Efficient Gba excision was confirmed in bone marrow, spleen, and thymus, with minimal recombination in the liver. In VavCre 129 GD mice, glucocerebrosidase activity in the spleen was severely reduced, leading to GlcCer and GlcSph accumulation and Gaucher cell infiltration in the spleen and femurs. Transcriptomic analysis identified upregulation of inflammatory and lysosomal pathways. Immune cell deconvolution from RNA-seq data further revealed an expansion of monocytes, dendritic cells, and pro-inflammatory macrophage subsets, suggesting an altered immune landscape. Additionally, GPNMB, a potential GD biomarker, was significantly elevated in both spleens and sera of VavCre 129 GD mice. This hematopoietic-specific GD model provides a powerful platform for studying GD pathophysiology, modifier genes, and immune dysregulation. It offers new opportunities for biomarker discovery and for developing strategies targeting hematopoietic and immune mechanisms in GD and related lysosomal storage disorders.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine (Digestive Diseases), Yale School of Medicine, The Anylan Center, 300 Cedar St, New Haven, Connecticut 06519, United States.
- Yale Center for Genome Analysis, Department of Medicine (Digestive Diseases), Yale School of Medicine, The Anylan Center, 300 Cedar St, New Haven, Connecticut 06519, United States.
Förderung
- NINDS NIH HHS
Zitieren
APA
Belinsky, G., Ruan, J., Fattahi, N., Mehta, S., Boddupalli, C. S., Mistry, P. K., & Nair, S. (2025). Modeling bone marrow microenvironment and hematopoietic dysregulation in Gaucher disease through VavCre mediated Gba deletion. Human Molecular Genetics. https://doi.org/10.1093/hmg/ddaf045
Vancouver
Belinsky G, Ruan J, Fattahi N, Mehta S, Boddupalli CS, Mistry PK, et al. Modeling bone marrow microenvironment and hematopoietic dysregulation in Gaucher disease through VavCre mediated Gba deletion. Human Molecular Genetics. 2025. doi:10.1093/hmg/ddaf045
BibTeX
@article{Belinsky2025,
author = {Belinsky, Glenn and Ruan, Jiapeng and Fattahi, Nima and Mehta, Sameet and Boddupalli, Chandra Sekhar and Mistry, Pramod K and Nair, Shiny},
title = {Modeling bone marrow microenvironment and hematopoietic dysregulation in Gaucher disease through VavCre mediated Gba deletion},
journal = {Human Molecular Genetics},
year = {2025},
doi = {10.1093/hmg/ddaf045}
}
EUVIMED